Pseudoxanthoma Elasticum: History
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:

Pseudoxanthoma elasticum (PXE) is a progressive disorder that is characterized by the accumulation of deposits of calcium and other minerals (mineralization) in elastic fibers.

  • genetic conditions

1. Introduction

Elastic fibers are a component of connective tissue, which provides strength and flexibility to structures throughout the body.

In PXE, mineralization can affect elastic fibers in the skin, eyes, and blood vessels, and less frequently in other areas such as the digestive tract. People with PXE may have yellowish bumps called papules on their necks, underarms, and other areas of skin that touch when a joint bends (flexor areas). They may also have abnormalities in the eyes, such as a change in the pigmented cells of the retina (the light-sensitive layer of cells at the back of the eye) known as peau d'orange. Another eye abnormality known as angioid streaks occurs when tiny breaks form in the layer of tissue under the retina called Bruch's membrane. Bleeding and scarring of the retina may also occur, which can cause vision loss.

Mineralization of the blood vessels that carry blood from the heart to the rest of the body (arteries) may cause other signs and symptoms of PXE. For example, people with this condition can develop narrowing of the arteries (arteriosclerosis) or a condition called claudication that is characterized by cramping and pain during exercise due to decreased blood flow to the arms and legs. Rarely, bleeding from blood vessels in the digestive tract may also occur.

2. Frequency

PXE affects approximately 1 in 50,000 people worldwide. For reasons that are unclear, this disorder is diagnosed twice as frequently in females as in males.

3. Causes

Mutations in the ABCC6 gene cause PXE. This gene provides instructions for making a protein called MRP6 (also known as the ABCC6 protein). This protein is found primarily in cells of the liver and kidneys, with small amounts in other tissues, including the skin, stomach, blood vessels, and eyes. MRP6 is thought to transport certain substances across the cell membrane; however, the substances have not been identified. Some studies suggest that the MRP6 protein stimulates the release of a molecule called adenosine triphosphate (ATP) from cells through an unknown mechanism. ATP can be broken down into other molecules, including adenosine monophosphate (AMP) and pyrophosphate. Pyrophosphate helps control deposition of calcium and other minerals in the body. Other studies suggest that a substance transported by MRP6 is involved in the breakdown of ATP. This unidentified substance is thought to help prevent mineralization of tissues.

Mutations in the ABCC6 gene lead to an absent or nonfunctional MRP6 protein. It is unclear how a lack of properly functioning MRP6 protein leads to PXE. This shortage may impair the release of ATP from cells. As a result, little pyrophosphate is produced, and calcium and other minerals accumulate in elastic fibers of the skin, eyes, blood vessels and other tissues affected by PXE. Alternatively, a lack of functioning MRP6 may impair the transport of a substance that would normally prevent mineralization, leading to the abnormal accumulation of calcium and other minerals characteristic of PXE.

The Gene Associated with Pseudoxanthoma Elasticum

  • ABCC6

4. Inheritance

PXE is inherited in an autosomal recessive manner, which means both copies of the gene in each cell have mutations. Most often, the parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but do not show signs and symptoms of the condition.

In a few cases, an affected individual has one affected parent and one parent without the signs and symptoms of the disorder. This situation resembles autosomal dominant inheritance, in which one copy of an altered gene in each cell is sufficient to cause a disorder and the mutation is typically inherited from one affected parent. In these cases of PXE, however, the parent without apparent symptoms has an ABCC6 gene mutation. The affected offspring inherits two altered genes, one from each parent. This appearance of autosomal dominant inheritance when the pattern is actually autosomal recessive is called pseudodominance.

5. Other Names for This Condition

  • Groenblad-Strandberg syndrome

  • Gronblad-Strandberg syndrome

  • PXE

This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/condition/pseudoxanthoma-elasticum

References

  1. Bercovitch L, Terry P. Pseudoxanthoma elasticum 2004. J Am Acad Dermatol. 2004Jul;51(1 Suppl):S13-4. Review.
  2. Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthomaelasticum: a clinical, pathophysiological and genetic update including 11 novelABCC6 mutations. J Med Genet. 2005 Dec;42(12):881-92.
  3. Dabisch-Ruthe M, Kuzaj P, Götting C, Knabbe C, Hendig D. Pyrophosphates as amajor inhibitor of matrix calcification in Pseudoxanthoma elasticum. J DermatolSci. 2014 Aug;75(2):109-20. doi: 10.1016/j.jdermsci.2014.04.015.
  4. Hu X, Plomp A, Wijnholds J, Ten Brink J, van Soest S, van den Born LI, Leys A,Peek R, de Jong PT, Bergen AA. ABCC6/MRP6 mutations: further insight into themolecular pathology of pseudoxanthoma elasticum. Eur J Hum Genet. 2003Mar;11(3):215-24.
  5. Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Váradi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P, van de Wetering K. ABCC6-mediated ATP secretion bythe liver is the main source of the mineralization inhibitor inorganicpyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1985-9. doi: 10.1161/ATVBAHA.114.304017.
  6. Jansen RS, Küçükosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K. ABCC6 prevents ectopic mineralizationseen in pseudoxanthoma elasticum by inducing cellular nucleotide release. ProcNatl Acad Sci U S A. 2013 Dec 10;110(50):20206-11. doi: 10.1073/pnas.1319582110.
  7. Laube S, Moss C. Pseudoxanthoma elasticum. Arch Dis Child. 2005Jul;90(7):754-6. Review.
  8. Le Saux O, Beck K, Sachsinger C, Silvestri C, Treiber C, Göring HH, JohnsonEW, De Paepe A, Pope FM, Pasquali-Ronchetti I, Bercovitch L, Marais AS, ViljoenDL, Terry SF, Boyd CD. A spectrum of ABCC6 mutations is responsible forpseudoxanthoma elasticum. Am J Hum Genet. 2001 Oct;69(4):749-64.Aug;71(2):448.
  9. Miksch S, Lumsden A, Guenther UP, Foernzler D, Christen-Zäch S, Daugherty C,Ramesar RK, Lebwohl M, Hohl D, Neldner KH, Lindpaintner K, Richards RI, Struk B. Molecular genetics of pseudoxanthoma elasticum: type and frequency of mutationsin ABCC6. Hum Mutat. 2005 Sep;26(3):235-48.
  10. Plomp AS, Hu X, de Jong PT, Bergen AA. Does autosomal dominant pseudoxanthoma elasticum exist? Am J Med Genet A. 2004 May 1;126A(4):403-12. Review.
  11. Ringpfeil F, McGuigan K, Fuchsel L, Kozic H, Larralde M, Lebwohl M, Uitto J.Pseudoxanthoma elasticum is a recessive disease characterized by compoundheterozygosity. J Invest Dermatol. 2006 Apr;126(4):782-6.
  12. Ringpfeil F, Pulkkinen L, Uitto J. Molecular genetics of pseudoxanthomaelasticum. Exp Dermatol. 2001 Aug;10(4):221-8. Review.
  13. Terry SF, Uitto J. Pseudoxanthoma Elasticum. 2001 Jun 5 [updated 2020 Jun 4]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington,Seattle; 1993-2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK1113/
More
This entry is offline, you can click here to edit this entry!
Video Production Service